Compile Data Set for Download or QSAR
Report error Found 29 Enz. Inhib. hit(s) with all data for entry = 10656
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557678(US11358953, Example 15)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557692(US11358953, Example 29)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557691(US11358953, Example 28 | US11753373, Compound H-2-...)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557690(US11358953, Example 27)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557689(US11358953, Example 26)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557688(US11358953, Example 25)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557687(US11358953, Example 24)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557686(US11358953, Example 23)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557672(US11358953, Example 9)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557664(US11358953, Example 2)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557668(US11358953, Example 5)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557669(US11358953, Example 6)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557670(US11358953, Example 7)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557671(US11358953, Example 8)
Affinity DataIC50: 100nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557673(US11358953, Example 10)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557666(US11358953, Example 3)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM509863(US11124497, Compound 393 | US11524940, Compound 39...)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557684(US11358953, Example 21)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557683(US11358953, Example 20)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557681(US11358953, Example 18)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557680(US11358953, Example 17)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557679(US11358953, Example 16)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557663(US11358953, Example 1)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557677(US11358953, Example 14)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557676(US11358953, Example 13)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557674(US11358953, Example 11)
Affinity DataIC50: 550nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557682(US11358953, Example 19)
Affinity DataIC50: 1.00E+3nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557685(US11358953, Example 22)
Affinity DataIC50: 1.00E+3nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM557675(US11358953, Example 12)
Affinity DataIC50: 1.00E+3nMAssay Description:SARS-CoV-2 3C-like (3CL) protease fluorescence assay (FRET): Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMRA-SITSAVLQSGFRKMK-Da...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/19/2022
Entry Details
Go to US Patent